TME Pharma N.V. (0N6A) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Pembrolizumab, Olaptesed Pegol | Metastatic Pancreatic Cancer | Phase II | Not Yet Recruiting | Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer | May 20, 2021 | ― |
| Pembrolizumab, Bevacizumab, Temozolomide (Tmz), Radiotherapy, Olaptesed Pegol | Glioblastoma | phase1AndPhase2 | Active Not Recruiting | Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients | Sep 25, 2019 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Pembrolizumab, Olaptesed Pegol | Phase II | Metastatic Pancreatic Cancer | Not Yet Recruiting | Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer | May 20, 2021 | ― |
| Pembrolizumab, Bevacizumab, Temozolomide (Tmz), Radiotherapy, Olaptesed Pegol | phase1AndPhase2 | Glioblastoma | Active Not Recruiting | Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients | Sep 25, 2019 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does TME Pharma N.V. (DE:0N6A) have in its pipeline
TME Pharma N.V. DE:0N6A is currently developing the following drugs: Pembrolizumab, Olaptesed Pegol, Pembrolizumab, Bevacizumab, Temozolomide (Tmz), Radiotherapy, Olaptesed Pegol. These drug candidates are in various stages of clinical development as the company works toward FDA approval.